- Home
- TFX vs CORT Comparison
TFX vs CORT Comparison
Compare TFX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TFX | CORT |
|---|---|---|
| Founded | 1943 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.7B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | TFX | CORT |
|---|---|---|
| Price | $107.80 | $33.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $140.29 | $105.20 |
| AVG Volume (30 Days) | 829.9K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | ★ $1,992,713,000.00 | $761,407,000.00 |
| Revenue This Year | $46.78 | $29.97 |
| Revenue Next Year | $3.86 | $30.25 |
| P/E Ratio | ★ N/A | $40.73 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $100.18 | $28.66 |
| 52 Week High | $143.32 | $117.33 |
Technical Indicators
Market Signals| Indicator | TFX | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 37.40 |
| Support Level | $102.03 | $28.66 |
| Resistance Level | $108.01 | $41.92 |
| Average True Range (ATR) | 3.57 | 1.26 |
| MACD | -1.15 | 0.29 |
| Stochastic Oscillator | 9.35 | 35.65 |
Price Performance
Historical ComparisonAbout TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.